Difference between revisions of "Team:BGU Israel"
| (34 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{BGU_Israel}} | {{BGU_Israel}} | ||
| + | <div id="homePage"> | ||
{{Template:BGU_Israel/header}} | {{Template:BGU_Israel/header}} | ||
| + | </div> | ||
<html lang="en"> | <html lang="en"> | ||
<body id="myPage" data-spy="scroll" data-target=".navbar" data-offset="60"> | <body id="myPage" data-spy="scroll" data-target=".navbar" data-offset="60"> | ||
| − | <header class="masthead text-center"> | + | <header class="img-responsive masthead text-center"> |
<div class="container my-auto"> | <div class="container my-auto"> | ||
</div> | </div> | ||
</header> | </header> | ||
| − | + | <div id="abstract" class="bg-white text-center"> | |
| − | <div id="abstract" class=" | + | |
<div class="row"> | <div class="row"> | ||
| − | <h1> | + | <div class="col-sm-4"> |
| − | <div class="col-sm- | + | </div> |
| − | <img src="https://static.igem.org/mediawiki/2018/5/51/T--BGU_Israel--home_char.png" | + | <div class="col-sm-8"> |
| + | <h1>What we are all about</h1> | ||
| + | </div> | ||
| + | |||
| + | <div class="col-sm-4 display"> | ||
| + | <img src="https://static.igem.org/mediawiki/2018/5/51/T--BGU_Israel--home_char.png" !important class="img-responsive"> | ||
| + | <br/> | ||
| + | <a href="https://2018.igem.org/Team:BGU_Israel/Description" class="btn btn-info" role="button" >Learn More</a> | ||
</div> | </div> | ||
| + | |||
<div class="col-sm-8"> | <div class="col-sm-8"> | ||
| − | <p | + | <p class="mb-4 justified">Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating neurodegenerative disease that affects motor neurons in the central nervous system. Recent research studies of ALS suggest that brain cells that have become toxic, directly contribute to the progression of the disease. These cells change their gene expression pattern and possess distinguishing genetic markers. In addition, they drive the death of other cells in the brain among them the motor neurons. <br><br> |
Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach: </p> | Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach: </p> | ||
| − | <ol class=" | + | <ol class="justified"> |
<li> We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.</li> | <li> We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.</li> | ||
<li>We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.</li> | <li>We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.</li> | ||
</ol> | </ol> | ||
| − | <p | + | <p class="mb-4 justified"> |
In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.</p> | In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.</p> | ||
</div> | </div> | ||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
</div> | </div> | ||
| Line 44: | Line 50: | ||
</div> | </div> | ||
</div> | </div> | ||
| + | <script> | ||
| + | document.querySelectorAll('a[href^="#"]').forEach(anchor => { | ||
| + | anchor.addEventListener('click', function (e) { | ||
| + | e.preventDefault(); | ||
| + | document.querySelector(this.getAttribute('href')).scrollIntoView({ | ||
| + | behavior: 'smooth' | ||
| + | }); | ||
| + | }); | ||
| + | }); | ||
| + | </script> | ||
</body> | </body> | ||
</html> | </html> | ||
{{Template:BGU_Israel/footer}} | {{Template:BGU_Israel/footer}} | ||
Latest revision as of 17:30, 17 October 2018
What we are all about
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, is a devastating neurodegenerative disease that affects motor neurons in the central nervous system. Recent research studies of ALS suggest that brain cells that have become toxic, directly contribute to the progression of the disease. These cells change their gene expression pattern and possess distinguishing genetic markers. In addition, they drive the death of other cells in the brain among them the motor neurons.
Our objective, as the BGU-IGEM team OriginALS, is to prolong survival of ALS patients via a novel genetic engineering approach. In order to reach this objective, we combine two separate strategies as our therapeutic approach:
- We identify and selectively eliminate only the toxic cells. In order to identify and target the toxic-cells only, we use distinguishing markers that are unique only to them.
- We prevent the generation of new toxic cells by genetically targeting specific molecules that generate the toxic cells.
In conclusion, our approach combines an apoptotic destruction of toxic cells with the prevention of the formation of new toxic cells, thus aiming to significantly reduce the occurrence of toxic cells in the central neuronal system (CNS), which is aimed at a significant deceleration of the progression rate of ALS.
Long Story Short